A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity

DOI: 10.1038/s41523-017-0052-4

Full-Text   Cite this paper   Add to My Lib

Abstract:

Patient characteristic

Full-Text